Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology
Rev Esp Cardiol (Engl Ed). 2020 Feb;73(2):161-167.
doi: 10.1016/j.rec.2019.08.012.
Epub 2019 Dec 7.
[Article in
English,
Spanish]
Authors
Carlos Escobar
1
, Manuel Anguita
2
, Vicente Arrarte
3
, Vivencio Barrios
4
, Ángel Cequier
5
, Juan Cosín-Sales
6
, Isabel Egocheaga
7
, Esteban López de Sa
8
, Luis Masana
9
, Vicente Pallarés
10
, Leopoldo Pérez de Isla
11
, Xavier Pintó
12
; Expert reviewers
Affiliations
- 1 Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain. Electronic address: [email protected].
- 2 Servicio de Cardiología, Hospital Reina Sofía, Córdoba, Spain.
- 3 Servicio de Cardiología, Hospital General Universitario, Alicante, Spain.
- 4 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- 5 Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- 6 Servicio de Cardiología, Hospital Arnau de Vilanova, Valencia, Spain.
- 7 Centro de Salud Isla de Oza, Madrid, Spain.
- 8 Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain.
- 9 Unitat de Medicina Vascular i Metabolisme, Hospital Universitari Sant Joan, Reus, Tarragona, Spain.
- 10 Unidad de Vigilancia de la Salud, Unión de Mutuas, Castellón, Spain.
- 11 Servicio de Cardiología, Hospital Universitario Clínico, Madrid, Spain.
- 12 Unidad de Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- 13 Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
Abstract
T***he current control of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease is very low and this is associated with an increase of cardiovascular outcomes. In addition, the latter this happens, the risk will be greater. This is mainly due to an insufficient use of the lipid-lowering therapy currently available. In fact, with current treatments (statins, ezetimibe and PCSK9 inhibitors), the majority of patients in secondary prevention should achieve low-density lipoprotein cholesterol goals. For these reasons, in this manuscript promoted by the Spanish Society of Cardiology we propose three simple and feasible decision-making algorithms that include the majority of clinical scenarios among patients with ischemic heart disease, with the double aim of attaining therapeutic goals in the majority of patients as soon as possible; in secondary prevention the magnitude of the benefit is risk- and time-dependent.
Keywords:
Cardiopatía isquémica; Ischemic heart disease; LDL-cholesterol; Lipid-lowering therapy; Prevención secundaria; Secondary prevention; Tratamiento hipolipemiante; cLDL.
Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Cardiology*
-
Cardiovascular Diseases / metabolism*
-
Consensus*
-
Humans
-
Lipid Metabolism*
-
Societies, Medical*
-
Spanien